Michel is co-founder and CEO of Mindsigns Health™ Inc a cloud-based neuropsychiatry platform with international collaborations and partnerships.
Michel is currently Director of Entrepreneurship and Research Translation at NTU-SCELSE, working on technology commercialization via spinoffs and industry collaborations and partnerships, strategy and corporate development.
During that time he was also responsible for the development and operations, from 2019-2022, of the Singapore National Biofilm Consortium, creating partnerships in the US, UK and EU and funding proof of concept and tech transfer projects between academia and industry.
Michel was a lecturer for the MIT-SMART ACT program where he developed and taught the course “Lab to Market”.
He is also co-founder and advisor to two other healthcare spinoffs involved in anti-microbials and microbiome.
Michel has held board positions with a number of technology and healthcare growth companies internationally, in operational and advisory roles and has managed technology & healthcare IPOs on both European markets and NASDAQ as well as M&A and investments.
Michel served as Vice Chairman of the Singapore Venture Capital Association (SVCA) and was a member of the Executive Council of BioSingapore. Michel won the SVCA’s Highest Impact VC/PE-Backed Company Non-Executive Board Member award in 2013
Michel holds a B.Sc. in Aerospace Engineering from the NYU Tandon School of Engineering (PINY) and attended General Electric’s Advanced Engineering program. Michel was a graduate of General Electric’s Edison Program. He earned his MBA from the London Business School and has certifications in machine learning, data privacy and QMS for Medtech.